RedHill Biopharma Ltd. [NASDAQ: RDHL] jumped around 0.04 points on Wednesday, while shares priced at $0.67 at the close of the session, up 6.08%. The company report on October 26, 2022 that RedHill Presents New Talicia® and Movantik® Data Analyses at ACG 2022.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Physiologically-Based Pharmacokinetic (PBPK) modeling study of Talicia evaluated intragastric antibiotic exposure, critical for successful H. pylori eradication, comparing low-dose rifabutin 50 mg every 8 hours to generic rifabutin triple therapy 150mg twice a day or 300 mg once a day. .
Talicia, the leading prescribed branded H. pylori therapy by U.S. gastroenterologists, is intended for empiric first-line eradication of H. pylori, a bacterial infection that affects approximately 35% of the U.S. adult population.
RedHill Biopharma Ltd. stock is now -74.15% down from its year-to-date (YTD) trading value. RDHL Stock saw the intraday high of $0.71 and lowest of $0.63 per share. The company’s 52-week high price is 5.89, which means current price is +44.92% above from all time high which was touched on 03/23/22.
Compared to the average trading volume of 2.88M shares, RDHL reached a trading volume of 3273139 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about RedHill Biopharma Ltd. [RDHL]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for RDHL shares is $7.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on RDHL stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for RedHill Biopharma Ltd. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on August 31, 2021. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on May 18, 2021, representing the official price target for RedHill Biopharma Ltd. stock.
The Average True Range (ATR) for RedHill Biopharma Ltd. is set at 0.09, with the Price to Sales ratio for RDHL stock in the period of the last 12 months amounting to 0.44.
How has RDHL stock performed recently?
RedHill Biopharma Ltd. [RDHL] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.93. With this latest performance, RDHL shares gained by 28.25% in over the last four-week period, additionally sinking by -61.45% over the last 6 months – not to mention a drop of -87.98% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for RDHL stock in for the last two-week period is set at 55.10, with the RSI for the last a single of trading hit 60.59, and the three-weeks RSI is set at 51.23 for RedHill Biopharma Ltd. [RDHL]. The present Moving Average for the last 50 days of trading for this stock 0.7149, while it was recorded at 0.5935 for the last single week of trading, and 1.4128 for the last 200 days.
RedHill Biopharma Ltd. [RDHL]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and RedHill Biopharma Ltd. [RDHL] shares currently have an operating margin of -94.61 and a Gross Margin at +42.39. RedHill Biopharma Ltd.’s Net Margin is presently recorded at -113.98.
Return on Equity for this stock declined to -860.29, with Return on Assets sitting at -54.12.
RedHill Biopharma Ltd.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.80 and a Current Ratio set at 1.00.
Insider trade positions for RedHill Biopharma Ltd. [RDHL]
There are presently around $2 million, or 9.70% of RDHL stock, in the hands of institutional investors. The top three institutional holders of RDHL stocks are: DISCIPLINED GROWTH INVESTORS INC /MN with ownership of 810,646, which is approximately -58.428% of the company’s market cap and around 12.96% of the total institutional ownership; GAGNON SECURITIES LLC, holding 375,346 shares of the stock with an approximate value of $0.25 million in RDHL stocks shares; and MILLENNIUM MANAGEMENT LLC, currently with $0.25 million in RDHL stock with ownership of nearly New of the company’s market capitalization.
Positions in RedHill Biopharma Ltd. stocks held by institutional investors increased at the end of November and at the time of the November reporting period, where 16 institutional holders increased their position in RedHill Biopharma Ltd. [NASDAQ:RDHL] by around 599,532 shares. Additionally, 18 investors decreased positions by around 2,431,145 shares, while 18 investors held positions by with 4,603 shares. The mentioned changes placed institutional holdings at 3,035,280 shares, according to the latest SEC report filing. RDHL stock had 5 new institutional investments in for a total of 404,947 shares, while 5 institutional investors sold positions of 1,216,572 shares during the same period.